Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 543

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin- E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry

Open access
Lemos, Pedro A., Serruys, Patrick W., van Domburg, Ron T., Saia, Francesco, Arampatzis, Chourmouzios A., Hoye, Angela, Degertekin, Muzaffer, Tanabe, Kengo, Daemen, Joost, Liu, Tommy K.K., McFadden, Eugene, Sianos, Georgios, Hofma, Sjoerd H., Smits, Pieter C., van der Giessen, Willem J., de Feyter, Pim J.·2004·Circulation

Abstract

Background— The effectiveness of sirolimus-eluting stents in unselected patients treated in the daily practice is currently unknown. Methods and Results— Sirolimus-eluting stent implantation has been used as the default strategy for all percutaneous procedures in our hospital as part of the R apamycin- E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) registry. Consecutive patients with de novo lesions (n=508) treated exclusively with sirolimus-eluting stents (SES group) were compared with 450 patients who received bare stents in the period just before (pre-SES group). Patients in the SES group more frequently had multivessel disease, more type C lesions, received more stents, and had more bifurcation stenting. At 1 year, the cumulative rate of major adverse cardiac events (death, myocardial infarction, or target vessel revascularization) was 9.7% in the SES group and 14.8% in the pre-SES group (hazard ratio [HR], 0.62 [95% CI, 0.44 to 0.89]; P =0.008). The 1-year risk of clinically driven target vessel revascularization in the SES group and in the pre-SES group was 3.7% versus 10.9%, respectively (HR, 0.35 [95% CI, 0.21 to 0.57]; P <0.001). Conclusions— Unrestricted utilization of sirolimus-eluting stents in the “real world” is safe and effective in reducing both repeat revascularization and major adverse cardiac events at 1 year compared with bare stent implantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000109138.84579.fa

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 543

Metadata

Authors
Lemos, P. A., Serruys, P. W., van Domburg, R. T., Saia, F., Arampatzis, C. A., Hoye, A., Degertekin, M., Tanabe, K., Daemen, J., Liu, T. K. K., McFadden, E., Sianos, G., Hofma, S. H., Smits, P. C., van der Giessen, W. J., & de Feyter, P. J.
Venue
Circulation
Published
2004-01-20
Volume
109
Issue
2
Pages
190-195
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2135866603
Cited by
543
References
9
FWCI
70.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin- E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry. https://app.cochat.ai/papers/10.1161/01.cir.0000109138.84579.fa
The paper
Lemos, P. A., Serruys, P. W., van Domburg, R. T., Saia, F., Arampatzis, C. A., Hoye, A., Degertekin, M., Tanabe, K., Daemen, J., Liu, T. K. K., McFadden, E., Sianos, G., Hofma, S. H., Smits, P. C., van der Giessen, W. J., & de Feyter, P. J. (2004). Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin- E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry. Circulation. https://doi.org/10.1161/01.cir.0000109138.84579.fa

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.